Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice

Endocrinology

Volumn 149, Issue 9, 2008, Pages 4322-4328

  Merani, S ^a   Truong, W ^a   Emamaullee, J A ^a   Toso, C ^a   Knudsen, L B ^c   Shapiro, A M J ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; LIRAGLUTIDE; RAPAMYCIN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENGRAFTMENT; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; GRAFT RECIPIENT; GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN LIKE ACTIVITY; INSULIN RELEASE; ISOGRAFT; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, EXPERIMENTAL; DRUG EVALUATION, PRECLINICAL; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE INTOLERANCE; GRAFT REJECTION; HOMEOSTASIS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, INBRED BALB C; SATIETY RESPONSE; STREPTOZOCIN;

EID: 50449094466     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-0501     Document Type: Article

References (34)

1. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV 2000 Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:230-238
2. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JR, Shapiro AM 2005 Five-year follow-up after clinical islet transplantation. Diabetes 54:2060-2069
3. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, Cagliero E, Alejandro R, Ryan EA, DiMercurio B, Morel P, Polonsky KS, Reems JA, Bretzel RG, Bertuzzi F, Froud T, Kandaswamy R, Sutherland DE, Eisenbarth G, Segal M, Preiksaitis J, Korbutt GS, Barton FB, Viviano L, Seyfert-Margolis V, Bluestone J, Lakey JR 2006 International trial of the Edmonton protocol for islet transplantation. N Engl J Med 355:1318-1330
4. Kneteman NM, Lakey JR, Wagner T, Finegood D 1995 Beneficial metabolic impact of the novel immunosuppressant rapamycin in chronic canine islet autograft recipients. Transplant Proc 27:3213
5. Fabian MC, Lakey JR, Rajotte RV, Kneteman NM 1993 The efficacy and toxicity of rapamycin in murine islet transplantation. In vitro and in vivo studies. Transplantation 56:1137-1142
6. Cantaluppi V, Biancone L, Romanazzi GM, Figliolini F, Beltramo S, Ninniri MS, Galimi F, Romagnoli R, Franchello A, Salizzoni M, Perin PC, Ricordi C, Segoloni GP, Camussi G 2006 Antiangiogenic and immunomodulatory effects of rapamycin on islet endothelium: relevance for islet transplantation. Am J Transplant 6:2601-2611
7. Cross SE, Richards SK, Clark A, Benest AV, Bates DO, Mathieson PW, Johnson PR, Harper SJ, Smith RM 2007 Vascular endothelial growth factor as a survival factor for human islets: effect of immunosuppressive drugs. Diabetologia 50:1423-1432
8. Bussiere CT, Lakey JR, Shapiro AM, Korbutt GS 2006 The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia 49:2341-2349
9. Drucker DJ, Nauck MA 2006 The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705
10. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, Thogersen H, Wilken M, Agerso H 2000 Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 43:1664-1669
11. Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, Santamaria P, Bluestone JA, Brillantes AM, Herold KC 2007 Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of β-cells. Endocrinology 148:5136-5144
12. Ogawa N, List JF, Habener JF, Maki T 2004 Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 53:1700-1705
13. Bohman S, Waern I, Andersson A, King A 2007 Transient beneficial effects of exendin-4 treatment on the function of microencapsulated mouse pancreatic islets. Cell Transplant 16:15-22
14. King A, Lock J, Xu G, Bonner-Weir S, Weir GC 2005 Islet transplantation outcomes in mice are better with fresh islets and exendin-4 treatment. Diabetologia 48:2074-2079
15. Sharma A, Sorenby A, Wernerson A, Efendic S, Kumagai-Braesch M, Tibell A 2006 Exendin-4 treatment improves metabolic control after rat islet transplantation to athymic mice with streptozotocin-induced diabetes. Diabetologia 49:1247-1253
16. Suen PM, Li K, Chan JC, Leung PS 2006 In vivo treatment with glucagon-like peptide 1 promotes the graft function of fetal islet-like cell clusters in transplanted mice. Int J Biochem Cell Biol 38:951-960
17. Ghofaili KA, Fung M, Ao Z, Meloche M, Shapiro RJ, Warnock GL, Elahi D, Meneilly GS, Thompson DM 2007 Effect of exenatide on β cell function after islet transplantation in type 1 diabetes. Transplantation 83:24-28
18. Fung M, Thompson D, Shapiro RJ, Warnock GL, Andersen DK, Elahi D, Meneilly GS 2006 Effect of glucagon-like peptide-1 (7-37) on β-cell function after islet transplantation in type 1 diabetes. Diabetes Res Clin Pract 74:189-193
19. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR 2004 Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 27:1335-1342
20. Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP, Verhoeven R, Buganova I, Madsbad S 2007 Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30:1608-1610
21. Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, Galecki A, Halter JB 2003 The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 52:1786-1791
22. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O 2004 One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53:1187-1194
23. Zhang N, Su D, Qu S, Tse T, Bottino R, Balamurugan AN, Xu J, Bromberg JS, Dong HH 2006 Sirolimus is associated with reduced islet engraftment and impaired β-cell function. Diabetes 55:2429-2436
24. Merani S, Schur C, Truong W, Knutzen VK, Lakey JR, Anderson CC, Ricordi C, Shapiro AM 2006 Compaction of islets is detrimental to transplant outcome in mice. Transplantation 82:1472-1476
25. Gotoh M, Maki T, Kiyoizumi T, Satomi S, Monaco AP 1985 An improved method for isolation of mouse pancreatic islets. Transplantation 40:437-438
26. Lacy PE, Kostianovsky M 1967 Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16:35-39
27. Emamaullee JA, Rajotte RV, Liston P, Korneluk RG, Lakey JR, Shapiro AM, Elliott JF 2005 XIAP overexpression in human islets prevents early posttransplant apoptosis and reduces the islet mass needed to treat diabetes. Diabetes 54:2541-2548
28. Flint A, Raben A, Astrup A, Holst JJ 1998 Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101:515-520
29. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M 2001 Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50:2530-2539
30. Parnaud G, Bosco D, Berney T, Pattou F, Kerr-Conte J, Donath MY, Bruun C, Mandrup-Poulsen T, Billestrup N, Halban PA 2008 Proliferation of sorted human and rat β cells. Diabetologia 51:91-100
31. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, Knudsen LB 2002 The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 283:E745-E752
32. Davalli AM, Ogawa Y, Ricordi C, Scharp DW, Bonner-Weir S, Weir GC 1995 A selective decrease in the β cell mass of human islets transplanted into diabetic nude mice. Transplantation 59:817-820
33. Teta M, Long SY, Wartschow LM, Rankin MM, Kushner JA 2005 Very slow turnover of β-cells in aged adult mice. Diabetes 54:2557-2567
34. Emamaullee JA, Stanton L, Schur C, Shapiro AM 2007 Caspase inhibitor therapy enhances marginal mass islet graft survival and preserves long-term function in islet transplantation. Diabetes 56:1289-1298